Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
NCT05711615 is a phase 1 interventional trial sponsored by National Cancer Institute (NCI). As of 21 Nov 2026, it is recruiting participants. It studies Doxorubicin and Nedisertib in Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma and 10 more conditions. The registry lists an enrollment of 30 participants at 16 sites in 1 country. The registry lists a start date of 6 Feb 2024 and a primary completion date of 3 May 2027. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05711615 |
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | National Cancer Institute (NCI) |
| Enrollment | 30 |
| Registered sites | 16 |
| Countries | 1 |
| Conditions | Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma and 6 more conditions |
| Drugs | Doxorubicin and Nedisertib |
| Start | 6 Feb 2024 |
| Primary completion | 3 May 2027 |
| Study completion | 3 May 2027 |
| Last update posted | 16 Nov 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Candace L Haddox
Dana-Farber - Harvard Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Los Angeles General Medical Center
Los Angeles
Mark AgulnikRecruiting - Usc / Norris Comprehensive Cancer Center
Los Angeles
Mark AgulnikRecruiting
- Uchealth University of Colorado Hospital
Aurora
Breelyn A. WilkyRecruiting
- University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami
Emily E. JonczakRecruiting
- University of Chicago Comprehensive Cancer Center
Chicago
Active, not recruiting - Uc Comprehensive Cancer Center at Silver Cross
New Lenox
Active, not recruiting - University of Chicago Medicine-Orland Park
Orland Park
Active, not recruiting
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore
H. Catherine WilburRecruiting - National Cancer Institute Developmental Therapeutics Clinic
Bethesda
A P. ChenRecruiting
- Dana-Farber Cancer Institute
Boston
Candace L. HaddoxRecruiting
- University of Michigan Rogel Cancer Center
Ann Arbor
Suspended
- Siteman Cancer Center-South County
St Louis
Mia C. WeissRecruiting - Washington University School of Medicine
St Louis
Mia C. WeissRecruiting
- Upmc Hillman Cancer Center
Pittsburgh
Melissa A. BurgessRecruiting
- Ut Md Anderson Cancer Center
Houston
Michael S. NakazawaRecruiting
- University of Virginia Cancer Center
Charlottesville
Paul V. ViscuseRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05711615
Each answer restates registry values shown on this page.
What is NCT05711615?
NCT05711615 is a phase 1 interventional trial sponsored by National Cancer Institute (NCI). It studies Doxorubicin and Nedisertib in Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma and 10 more conditions.
Is NCT05711615 recruiting?
As of 21 Nov 2026, it is recruiting participants. 12 of its 16 sites list their own status as recruiting.
Who leads NCT05711615?
The registry names Candace L Haddox (principal investigator, Dana-Farber - Harvard Cancer Center LAO) as the overall official.
Where does NCT05711615 run?
The registry lists 16 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT05711615 study?
The registered drug and biological interventions are Doxorubicin and Nedisertib.
When is NCT05711615 expected to complete?
The registry lists a primary completion date of 3 May 2027 and a study completion date of 3 May 2027. The sponsor last updated the record on 16 Nov 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.